Samer Hassan, MD
Hematology & Oncology · Oklahoma City, OKNPI 1033421284
Payments from drug & device makers
Across 75 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$212
- Novartis$182
- Lilly USA, LLC$150
- AbbVie$90
- AstraZeneca$84
- Sanofi$84
- plus $744 from 22 others
What the payments were for
- Food & beverage$1,22079%
- Education$32621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $212 |
| Novartis | 8 | $182 |
| Lilly USA, LLC | 4 | $150 |
| AbbVie | 4 | $90 |
| AstraZeneca(2 entities) | 5 | $84 |
| Sanofi | 4 | $84 |
| Gilead | 5 | $81 |
| Merck | 5 | $76 |
| Genentech USA, Inc. | 4 | $72 |
| Bristol Myers Squibb | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Incyte Corporation | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Johnson & Johnson(2 entities) | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Array Biopharma Inc | 1 | $26 |
| Beigene USA, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Seagen Inc. | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $19 |
| Geron Corporation | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Amgen | 1 | $14 |
How this compares
$1,546 in reported general payments places this provider in the 30th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 35 | $639,556 |
| RevlimidLenalidomide | 34 | $478,906 |
| TasignaNilotinib Hcl | 32 | $377,787 |
| VerzenioAbemaciclib | 21 | $315,668 |
| CalquenceAcalabrutinib Maleate | 18 | $226,147 |
| IbrancePalbociclib | 12 | $192,757 |
| JakafiRuxolitinib Phosphate | 24 | $184,899 |
| BrukinsaZanubrutinib | 25 | $184,675 |
| Lenalidomide | 14 | $181,549 |
| InlytaAxitinib | 14 | $180,254 |
| PromactaEltrombopag Olamine | 18 | $160,562 |
| XtandiEnzalutamide | 17 | $154,726 |
| BraftoviEncorafenib | 13 | $143,148 |
| EliquisApixaban | 138 | $92,711 |
| LumakrasSotorasib | 11 | $58,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $35 | $639,55635 claims |
| NovartisTasigna, Promacta | $182 | $538,34950 claims |
| Bristol Myers SquibbRevlimid | $54 | $478,90634 claims |
| PfizerIbrance, Inlyta, Eliquis | $212 | $465,721164 claims |
| Lilly USA, LLCVerzenio | $150 | $315,66821 claims |
| AstraZenecaCalquence | $84 | $226,14718 claims |
| Incyte CorporationJakafi | $32 | $184,89924 claims |
| Beigene USA, Inc.Brukinsa | $25 | $184,67525 claims |
| Astellas Pharma US IncXtandi | $23 | $154,72617 claims |
| Array Biopharma IncBraftovi | $26 | $143,14813 claims |
| AmgenLumakras | $14 | $58,61711 claims |
| Johnson & JohnsonXarelto | $32 | $19,19224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Adam AschOklahoma City$2M
- Adanma Anji Ayanambakkam AttanathiOklahoma City$1.9M
- Hassan HatoumOklahoma City$1.4M
- Abdul Rafeh NaqashOklahoma City$1.1M
- Sami IbrahimiOklahoma City$1M
- Carrie YuenOklahoma City$564K
- David LamOklahoma City$445K
- Romeo MandanasOklahoma City$419K
- Carla KurkjianOklahoma City$310K
- Sonia VargheseOklahoma City$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.